CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary cancers.
  
  LEARNING OBJECTIVES

  • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first-line therapy for patients with unresectable or metastatic hepatocellular carcinoma (HCC).
  • Appreciate Phase III data leading to the FDA approval of novel first-line treatment strategies for unresectable or metastatic HCC, and discuss how these can be optimally integrated into the clinical care of patients with this disease.
  • Evaluate the rationale for and available and emerging data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for patients with HCC in order to determine the current and future roles of these novel regimens.
  • Establish an evidence-based approach to the selection and sequencing of available therapeutic options for progressive HCC.
  • Discuss the biologic justification for the evaluation of immune checkpoint inhibitors for patients with advanced biliary tract cancers, and review available and emerging data with the use of anti-PD-1/PD-L1 antibody-based approaches.
  • Recognize the molecular heterogeneity of cholangiocarcinomas and other biliary tract cancers, and appreciate the biologic rationale for efforts to exploit documented abnormalities in patients with these diseases.
  • Assess key data sets supporting the recent FDA approvals of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
  • Recall available and emerging data with investigational agents and strategies currently in clinical testing for hepatobiliary cancers, and where applicable, refer eligible patients for trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Ghassan Abou-Alfa, MD, MBA
  Professor
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Autem Medical, Berry Genomics, BioNTech SE, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Eisai Inc, Exelixis Inc, FibroGen Inc, Genentech, a member of the Roche Group, Helio Health, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Merus BV, Neogene Therapeutics, NewBridge Pharmaceuticals, Novartis, QED Therapeutics, Servier Pharmaceuticals LLC, Tempus, Thetis Pharmaceuticals, Vector Pharma, Yiviva; Contracted Research: Agenus Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Digestive Care Inc, Elicio Therapeutics, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Puma Biotechnology Inc, QED Therapeutics, Yiviva; Nonrelevant Financial Relationship: Parker Institute for Cancer Immunotherapy.
  
  Richard S Finn, MD
  Professor, Department of Medicine, Division of Hematology/Oncology
  David Geffen School of Medicine at UCLA
  Director, Signal Transduction and Therapeutics Program
  Jonsson Comprehensive Cancer Center at UCLA
  Los Angeles, California
  
  Advisory Committee: CStone Pharmaceuticals; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, CStone Pharmaceuticals, Eisai Inc, Exelixis Inc, Genentech, a member of the Roche Group, Hengrui Therapeutics Inc, Lilly, Merck, Pfizer Inc; Contracted Research (paid to UCLA): Adaptimmune, Bayer HealthCare Pharmaceuticals, Bristol Myers Squibb, Eisai Inc, Lilly, Merck, Pfizer Inc, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP; Speakers Bureau: Genentech, a member of the Roche Group.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Elevation Oncology Inc, Exelixis Inc, Incyte Corporation, and Taiho Oncology Inc.
  
  Release date: May 2023
  Expiration date: May 2024